×
About 1,838,644 results

SARS-CoV-2 infection in conjunctival tissue
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30272-1/fulltext

In a recent study published in The Lancet Respiratory Medicine in May, 2020, Kenrie Hui and colleagues1 described the tropism, replication competence, and innate immune responses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the human respiratory tract and conjunctiva. The authors concluded that SARS-CoV-2 replication in the conjunctiva was greater than SARS-CoV replication...

Assessment of patients who tested positive for COVID-19 after recovery
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30433-3/fulltext

Since the start of the outbreak in December 2019, COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), has led to an increasing number of infections worldwide, with an estimated overall mortality of 5·7%.1 Meanwhile, many patients who were hospitalised have recovered and were discharged to self-quarantine. However, some patients have tested positive for COVID-19 aga...

Kinetics of viral load and antibody response in relation to COVID-19 severity
https://dm5migu4zj3pb.cloudfront.net/manuscripts/138000/138759/cache/138759.1-20200701111152-covered-253bed37ca4c1ab43d105aefdf7b5536.pdf

The SARS-CoV-2 is the causative agent for COVID-19 pneumonia. Little is known about the 60 kinetics, tissue distribution, cross-reactivity and neutralization antibody response in COVID61 19 patients. Two groups of RT-PCR confirmed COVID-19 patients were enrolled in this study, 62 including 12 severe patients in ICUs who needed mechanical ventilation and 11 mild patients 63 in isolation wards...

Liver injury in COVID-19: management and challenges
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30057-1/fulltext

In December, 2019, an outbreak of a novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], previously 2019-nCoV) started in Wuhan, China, and has since become a global threat to human health. The number of confirmed cases of 2019 coronavirus disease (COVID-19) has reached 87 137 worldwide as of March 1, 2020, according to WHO COVID-19 situation report 41; most of the...

Adaptive immunity to SARS-CoV-2
https://academic.oup.com/ooim/article/doi/10.1093/oxfimm/iqaa003/5869360?searchresult=1

The majority of SARS-CoV-2 exposed individuals mount an antibody response within around 2-weeks and spike antigen binding responses correlate well with functional virus neutralisation. A minority make little detectable antibody, generally those with either very mild/asymptomatic disease or those with severe/lethal infection. However, in general, antibody titre correlates with viral load and dur...

Pre-existing immunity to SARS-CoV-2: the knowns and unknowns
https://www.nature.com/articles/s41577-020-0389-z

T cell reactivity against SARS-CoV-2 was observed in unexposed people; however, the source and clinical relevance of the reactivity remains unknown. It is speculated that this reflects T cell memory to circulating ‘common cold’ coronaviruses. It will be important to define specificities of these T cells and assess their association with COVID-19 disease severity and vaccine responses.

Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?
https://link.springer.com/article/10.1007/s00406-019-00982-6
European Archives of Psychiatry and Clinical Neuroscience;

Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by motor symptoms such as bradykinesia, rest tremor, postural disturbances, and rigidity. PD is also characterized by non-motor symptoms such as sleep disturbances, cognitive deficits, and psychiatric disorders such as psychosis, depression, and anxiety. The pharmacological treatment for these symptoms is limited in ...

Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700135/
Scientific Reports;

Chronic levodopa treatment leads to the appearance of dyskinesia in the majority of Parkinson’s disease patients. Neurovascular dysregulation in putaminal and pallidal regions is thought to be an underlying feature of this complication of treatment. We used microPET to study unilaterally lesioned 6-hydroxydopamine rats that developed levodopa-induced abnormal involuntary movements (AIMs) after ...

Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283839/
NPJ Parkinson's Disease;

IRL790 is a novel compound with psychomotor stabilizing properties primarily targeting the dopamine D3 receptor. IRL790 is developed as an experimental treatment for levodopa-induced dyskinesia (LID), impulse control disorder, and psychosis in Parkinson’s disease (PD). The primary objective was to investigate the safety and tolerability of IRL790 in PD patients with LID in a randomized controll...

Neural substrates and potential treatments for levodopa-induced dyskinesias in Parkinson’s disease
https://www.degruyter.com/view/journals/revneuro/27/7/article-p729.xml
Reviews in the Neurosciences;

Parkinson’s disease (PD) is primarily a motor disorder that involves the gradual loss of motor function. Symptoms are observed initially in the extremities, such as hands and arms, while advanced stages of the disease can effect blinking, swallowing, speaking, and breathing. PD is a neurodegenerative disease, with dopaminergic neuronal loss occurring in the substantia nigra pars compacta, thus ...

Dysfunctional inhibitory control in Parkinson’s disease patients with levodopa-induced dyskinesias
https://link.springer.com/article/10.1007/s00415-018-8945-1
Journal of Neurology;

Chronic dopamine replacement therapies in Parkinson’s disease can induce side effects, such as levodopa-induced dyskinesias and impulse control disorders. A dysfunction of inhibitory brain networks has been related to both disorders; however, there is no clear behavioral evidence supporting this hypothesis. We aimed to determine whether PD patients with levodopa-induced dyskinesias show feature...

Lisocabtagene maraleucel CAR T shows durable response in large B-cell NHL
https://www.healio.com/news/hematology-oncology/20200709/lisocabtagene-maraleucel-car-t-shows-durable-response-in-large-bcell-nhl

Jul 8th, 2020 - In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.

Olaparib shows 1-year survival benefit in recurrent ovarian cancer, BRCA mutations
https://www.healio.com/news/hematology-oncology/20200707/olaparib-shows-1year-survival-benefit-in-recurrent-ovarian-cancer-brca-mutations

Jul 6th, 2020 - Overall survival results from SOLO-2 showed patients with recurrent ovarian cancer and germline BRCA mutations added a year of life when treated with olaparib only, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Retreatment with CAR-T therapy shows clinical efficacy in lymphoma
https://www.healio.com/news/hematology-oncology/20200708/retreatment-with-cart-therapy-shows-clinical-efficacy-in-lymphoma

Jul 7th, 2020 - In a small sample, retreatment of patients with large B-cell lymphoma showed good response, notably in patients who had complete response on initial treatment, according to a poster presented at ASCO 2020 Virtual Scientific Program.

Patient survival greatly impacted by selection for ovarian cancer relapse surgery
https://www.healio.com/news/hematology-oncology/20200707/patient-survival-greatly-impacted-by-selection-for-ovarian-cancer-relapse-surgery

Jul 6th, 2020 - Studies presented during the ASCO2020 Virtual Scientific Program showed the benefit of validated selection tools in pursuing surgical measures for ovarian cancer relapse, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Herpes Zoster Ophthalmicus
https://www.aao.org/eyenet/article/herpes-zoster-ophthalmicus-pearls

Herpes zoster (HZ), or shingles, results from reactivation of latent infection with varicella- zoster virus, which also causes chicken­pox. Anyone who has had chickenpox, even in subclinical form, is at risk for developing HZ. It is estimated that the lifetime risk of HZ is 30%, and 1 mil­lion new cases are reported annually in the United States.1 An effective shingles vaccine has been approved...

The serotonergic system in Parkinson’s patients with dyskinesia: evidence from imaging studies
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060863/

The purpose of review is to review the current status of positron emission tomography (PET) molecular imaging of serotonergic system in Parkinson’s patients who experience levodopa-induced (LIDs) and graft-induced dyskinesias (GIDs). PET imaging studies have shown that Parkinson’s disease is characterized by progressive loss of dopaminergic and serotonergic neurons. Parkinson’s patients who exp...

Sensory Tricks for Cervical Levodopa‐induced Dyskinesia in Patients with Parkinson's Disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407061/

Choreiform or dystonic movement in the craniocervical region can occur as levodopa‐induced dyskinesia (LID). “Sensory tricks” are various alleviating maneuvers for the relief of abnormal postures in patients who have idiopathic focal dystonia, particularly those who have cervical dystonia. The authors report on three men with Parkinson's disease who had been receiving levodopa for more than 3 y...

Dopamine Transporter Density in de novo Parkinson's Disease Does Not Relate to the Development of Levodopa-Induced Dyskinesias
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901354/

In Parkinson’s disease (PD), the onset of levodopa-induced dyskinesias (LIDs) is difficult to predict. This study examines whether dopamine transporter (DAT)-specific SPECT imaging in de novo PD relates to later development of LIDs.

The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure
https://journals.sagepub.com/doi/full/10.1177/2050313X20933473

The COVID-19 pandemic has brought about an urgent need for effective treatment, while conserving vital resources such as intensive care unit beds and ventilators. Antivirals, convalescent plasma, and biologics have been used with mixed results. The profound “cytokine storm” induced endotheliopathy and microthrombotic disease in patients with COVID-19 may lead to acute respiratory distress syndr...